SCHEMBL426346

SCHEMBL426346

c1ccc2c(c1)[nH]c1ccc(Nc3cc(OCCN4CCOCC4)cc(N4CCOCC4)n3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
TTK P33981 1/20 0.46
AURKB Q96GD4 1/20 0.46
LTA4H P09960 1/20 0.44
GRM4 Q14833 4/20 0.44
PDGFRB P09619 2/20 0.44
PDGFRA P16234 1/20 0.44
FGFR1 P11362 1/20 0.44
KDR P35968 1/20 0.44
AIMP2 Q13155 1/20 0.42
MAPK14 Q16539 1/20 0.41
BACE1 P56817 3/20 0.41
AXL P30530 2/20 0.41
MAOA P21397 1/20 0.41
PRKCQ Q04759 2/20 0.40
PIK3CA P42336 1/20 0.40
AKT1 P31749 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428542 0.87 AURKA (0.46) AURKACCNA2CDK2TTKAURKB
SCHEMBL425165 0.85 MCHR1 (0.47) AURKACCNA2CDK2TTKAURKB
SCHEMBL14412450 0.83 AURKA (0.43) AURKACCNA2CDK2TTKAURKB
SCHEMBL430604 0.83 AIMP2 (0.47) AURKACCNA2CDK2TTKAURKB
SCHEMBL425961 0.82 AIMP2 (0.50) AURKACCNA2CDK2TTKAURKB
SCHEMBL425682 0.82 LTA4H (0.50) LTA4HPDGFRBPDGFRAFGFR1KDR
SCHEMBL426452 0.81 AIMP2 (0.45) AURKACCNA2CDK2TTKAURKB
SCHEMBL14262741 0.78 PRKCQ (0.53) AURKACCNA2CDK2TTKAURKB
SCHEMBL429008 0.75 HSD17B10 (0.40) AURKAAURKBKDRPIK3CA
SCHEMBL14131870 0.75 MAPT (0.50) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687004-A4 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2009-04-08 EP claimed
JP-2007510747-A 2007-04-26 JP claimed
EP-1687004-A2 PYRIDINE COMPOUNDS Synta Pharmaceuticals Corporation (US) 2006-08-09 EP claimed
US-20050250774-A1 Pyridine compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 US claimed
WO-2005046603-A2 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS, CORP. (US) 2005-05-26 WO claimed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 US disclosed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 US disclosed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 US disclosed
US-20120021434-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-01-26 US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 US disclosed
WO-2007050980-A2 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2007-05-03 WO disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 US disclosed
US-20050250774-A1 Pyridine compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167300-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 AURKA 1791/4885CCNA2 2539/4885CDK2 1637/4885
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS REL, NFATC1, BCL6 AURKA 4825/4885CCNA2 2248/4885CDK2 3233/4885
US-20050250774-A1 Pyridine compounds IL2, IL4, IL6 AURKA 1791/4885CCNA2 2539/4885CDK2 1637/4885
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders REL, NFATC1, BCL6 AURKA 4825/4885CCNA2 2248/4885CDK2 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.